Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV postexposure prophylaxis: Who should get it?

Doug Campos-Outcalt1

  • 1Department of Family and Community Medicine, University of Arizona College of Medicine, 4001 North Third Street #415, Phoenix, AZ 85012, USA. dougco@u.arizona.edu

The Journal of Family Practice
|July 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

US Preventive Services Task Force: What Does the Future Hold?

American family physician·2026
Same author

Advisory Committee on Immunization Practices Standards for Assessing Evidence.

JAMA·2025
Same author

Practice Alert: Meningococcal Vaccines.

American family physician·2025
Same author

Practice Alert: Pneumococcal Conjugate Vaccines Approved for Adults.

American family physician·2025
Same author

Practice Alert: CDC Guidelines on Doxycycline for STI Postexposure Prophylaxis.

American family physician·2024
Same author

Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.

MMWR. Morbidity and mortality weekly report·2024

Deciding on HIV postexposure prophylaxis (PEP) can be complex due to incomplete risk information, low infection rates, and potential medication side effects. This article summarizes the latest CDC guidelines for HIV PEP decisions.

Area of Science:

  • Public Health
  • Infectious Diseases
  • Occupational Health

Background:

  • HIV postexposure prophylaxis (PEP) is typically reserved for healthcare workers in high-risk exposure settings.
  • Decisions regarding PEP are often complicated by incomplete risk assessments and patient anxiety.
  • Factors influencing PEP decisions include low infection risk, undefined protection levels, and potential medication side effects.

Purpose of the Study:

  • To provide a concise overview of the Centers for Disease Control and Prevention's (CDC) current recommendations for HIV postexposure prophylaxis (PEP).
  • To assist healthcare providers and individuals in navigating the complexities of HIV exposure risk assessment and PEP decision-making.

Main Methods:

  • This article synthesizes the most recent guidance issued by the Centers for Disease Control and Prevention (CDC) regarding HIV PEP.

Related Experiment Videos

  • Information is distilled from official CDC publications on occupational and nonoccupational HIV exposure.

    • Main Results:

    • The article highlights the complexities involved in determining the necessity of PEP.
    • It addresses the psychological impact of potential HIV exposure, including fear and anxiety.
    • Key considerations such as incomplete exposure risk data, generally low infection probabilities, and the known side effects of PEP medications are discussed.

    Conclusions:

    • The decision to initiate HIV PEP requires careful consideration of multiple factors, balancing potential benefits against risks and uncertainties.
    • Adherence to updated CDC guidelines is crucial for appropriate and effective management of HIV exposures.
    • Further clarity on PEP efficacy and risk stratification may aid future decision-making processes.